| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
HPV infection is one of the etiologic factor of head and neck cancer.The E6 and E7 genes of HPVs encode proteins, that interfere with function of the function of the tumor suppressor proteins p53 and Rb.We explored the potential use of antisense HPV RNA transcripts foe gene therapy for HPV-positive head and neck cancers.We introduced the antisense RNA transcripts of E7 gene of HPV type 16 into human oral cancer SCC-47 cells harboring HPV 16 via recombinant adenoviral vector, Ad-AS E7.
After infection, cell growth and tumorigenecity were suppressed in vitro. Moreover, we studied the effect of Ad-AS E7 as a potential chemosensitizer of cislatin (CDDP).The combination of CDDP and Ad-AS E7 treatment was significantly superior to either modality alone.
Our results suggest that introduction of Ad-AS E7 may be an effective sensitizer of CDDP chemotherapy in HPV-positive head and neck cancers.
|
